Fig. 9: Interfering with macrophage-iNKT cell interactions synergizes with inhibiting VCAM1 signaling to improve efficacy of iNKT cell-based immunotherapy. | Nature Communications

Fig. 9: Interfering with macrophage-iNKT cell interactions synergizes with inhibiting VCAM1 signaling to improve efficacy of iNKT cell-based immunotherapy.

From: Motility and tumor infiltration are key aspects of invariant natural killer T cell anti-tumor function

Fig. 9

a Timeline of experimental procedure for (b–d). NTC, none target control. b–d Picture (b), weight (c), and growth curves (d) of Vcam1 knockdown MC38 tumors and NTC MC38 tumors in Lyz2cre Cd1d1fl/fl mice or Cd1d1fl/fl mice receiving iNKT cells plus αGC (n = 10 mice per group). e Timeline of experimental procedure for (f, g). f, g Weight (f), and growth curves (g) of MC38 tumors in WT mice receiving iNKT cells plus αGC combined with anti-VCAM1 antibody lone or PLX3397 (40 mg kg−1) alone or anti-VCAM1 antibody plus PLX3397 in combination (n = 7–8 mice per group). IgG isotype control antibody and DMSO were used as negative controls. Data are represented as mean ± SEM, and were analyzed by one-way ANOVA (c, f) and two-way ANOVA (d, g). Source data are provided as a Source Data file.

Back to article page